

Hua Jin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11342323/publications.pdf>

Version: 2024-02-01

43
papers

3,262
citations

279798

23
h-index

254184

43
g-index

44
all docs

44
docs citations

44
times ranked

3674
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased prevalence of metabolic syndrome in Veterans with PTSD untreated with antipsychotic medications. <i>International Journal of Mental Health</i> , 2023, 52, 45-60.	1.3	3
2	Sulforaphane Effects on Cognition and Symptoms in First and Early Episode Schizophrenia: A Randomized Double-Blind Trial. <i>Schizophrenia Bulletin Open</i> , 2022, 3, .	1.7	3
3	OUP accepted manuscript. <i>Schizophrenia Bulletin</i> , 2022, , .	4.3	1
4	Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. <i>Schizophrenia Research</i> , 2021, 230, 87-94.	2.0	2
5	Decreasing risk of psychosis by sulforaphane study protocol for a randomized, double-blind, placebo-controlled, clinical multi-centre trial. <i>Microbial Biotechnology</i> , 2021, 15, 585-594.	1.7	6
6	Gene expression of methylation cycle and related genes in lymphocytes and brain of patients with schizophrenia and non-psychotic controls. <i>Biomarkers in Neuropsychiatry</i> , 2021, 5, 100038.	1.0	7
7	Effects of transcranial direct current stimulation on cognition and symptoms in Chinese patients with schizophrenia. <i>Psychiatry Research</i> , 2020, 284, 112617.	3.3	8
8	Clinical Correlates of Insulin Resistance in Chronic Schizophrenia: Relationship to Negative Symptoms. <i>Frontiers in Psychiatry</i> , 2019, 10, 251.	2.6	13
9	Cognitive deficits in subjects at risk for psychosis, first-episode and chronic schizophrenia patients. <i>Psychiatry Research</i> , 2019, 274, 235-242.	3.3	20
10	A novel biomarker of cardiometabolic pathology in schizophrenia?. <i>Journal of Psychiatric Research</i> , 2019, 117, 31-37.	3.1	10
11	What is the optimal neuropsychological test battery for schizophrenia in China?. <i>Schizophrenia Research</i> , 2019, 208, 317-323.	2.0	22
12	Betahistidine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. <i>Psychopharmacology</i> , 2018, 235, 3545-3558.	3.1	25
13	Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial. <i>PLoS ONE</i> , 2016, 11, e0143490.	2.5	52
14	Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2095-2104.	2.2	3
15	Subtype associations with HIV-associated neurocognitive disorder in China. <i>Journal of NeuroVirology</i> , 2016, 22, 246-250.	2.1	5
16	Regional white matter abnormalities in drug-naive, first-episode schizophrenia patients and their healthy unaffected siblings. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 246-254.	2.3	25
17	The MATRICS Consensus Cognitive Battery (MCCB): Co-norming and standardization in China. <i>Schizophrenia Research</i> , 2015, 169, 109-115.	2.0	176
18	Absence of neurocognitive impairment in a large Chinese sample of HCV-infected injection drug users receiving methadone treatment. <i>Drug and Alcohol Dependence</i> , 2014, 137, 29-35.	3.2	16

#	ARTICLE	IF	CITATIONS
19	Decreased left middle temporal gyrus volume in antipsychotic drug-naïve, first-episode schizophrenia patients and their healthy unaffected siblings. <i>Schizophrenia Research</i> , 2013, 144, 37-42.	2.0	84
20	Comparison of Longer-Term Safety and Effectiveness of 4 Atypical Antipsychotics in Patients Over Age 40. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 10-18.	2.2	46
21	Metabolic Syndrome: Relative Risk Associated with Post-Traumatic Stress Disorder (PTSD) Severity and Antipsychotic Medication Use. <i>Psychosomatics</i> , 2012, 53, 550-558.	2.5	26
22	The Influence of HLA on HIV-Associated Neurocognitive Impairment in Anhui, China. <i>PLoS ONE</i> , 2012, 7, e32303.	2.5	12
23	Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. <i>Schizophrenia Research</i> , 2011, 125, 295-299.	2.0	53
24	Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: A naturalistic 12-month follow-up study. <i>Neuroscience Letters</i> , 2011, 503, 141-146.	2.1	34
25	Psychiatric context of Human Immunodeficiency Virus infection among former plasma donors in rural China. <i>Journal of Affective Disorders</i> , 2011, 130, 421-428.	4.1	11
26	Neuropsychological Performance in Mainland China: The Effect of Urban/Rural Residence and Self-Reported Daily Academic Skill Use. <i>Journal of the International Neuropsychological Society</i> , 2011, 17, 163-173.	1.8	28
27	APOE ϵ 4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors. <i>Aids</i> , 2010, 24, 1471-1479.	2.2	49
28	Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. <i>Aids</i> , 2010, 24, 983-990.	2.2	52
29	Effect of Antipsychotic Medication Alone vs Combined With Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia. <i>Archives of General Psychiatry</i> , 2010, 67, 895.	12.3	124
30	Use of Clinical Markers to Identify Metabolic Syndrome in Antipsychotic-Treated Patients. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1273-1278.	2.2	18
31	Discontinuation of Quetiapine From an NIMH-Funded Trial Due to Serious Adverse Events. <i>American Journal of Psychiatry</i> , 2009, 166, 937-938.	7.2	8
32	Association of Posttraumatic Stress Disorder With Increased Prevalence of Metabolic Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 210-215.	1.4	57
33	Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. <i>Journal of NeuroVirology</i> , 2008, 14, 536-549.	2.1	82
34	Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. <i>Schizophrenia Research</i> , 2008, 100, 70-85.	2.0	133
35	Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 185-93.	7.4	316
36	Neurobehavioral effects of HIV-1 infection in China and the United States: A pilot study. <i>Journal of the International Neuropsychological Society</i> , 2007, 13, 781-90.	1.8	45

#	ARTICLE	IF	CITATIONS
37	A lifestyle intervention for older schizophrenia patients with diabetes mellitus: A randomized controlled trial. <i>Schizophrenia Research</i> , 2006, 86, 36-44.	2.0	174
38	Successful aging in Shanghai, China: definition, distribution and related factors. <i>International Psychogeriatrics</i> , 2006, 18, 551.	1.0	81
39	Depression and suicidality in HIV/AIDS in China. <i>Journal of Affective Disorders</i> , 2006, 94, 269-275.	4.1	93
40	Atypical antipsychotics and glucose dysregulation: a systematic review. <i>Schizophrenia Research</i> , 2004, 71, 195-212.	2.0	187
41	Phenomenology of and Risk Factors for New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated With Atypical Antipsychotics: An Analysis of 45 Published Cases. <i>Annals of Clinical Psychiatry</i> , 2002, 14, 59-64.	0.6	159
42	Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. <i>Annals of Clinical Psychiatry</i> , 2002, 14, 59-64.	0.6	95
43	The prevalence of dementia and Alzheimer's disease in Shanghai, China: Impact of age, gender, and education. <i>Annals of Neurology</i> , 1990, 27, 428-437.	5.3	897